Founded in 2009 by Tino Alavie, Qvella develops molecular diagnostics intended to reduce time-to-result in the diagnosis of infections. Its Field Activated Sample Treatment (FAST) technology uses an electrical lysing and sample treatment technique to enable rapid detection of infectious agents from direct blood samples. The platform removes the need for culturing or time-consuming sample processing and focuses on point-of-need pathogen detection. Qvella recently closed a US$20m Series B financing to support its next stage of development. The company intends to use the funds to conduct clinical trials, support ongoing research and development, and facilitate team expansion and manufacturing scale-up. Qvella is headquartered in Toronto, Canada. Qvella develops a rapid molecular diagnostics platform aimed at reducing time-to-result for infection diagnosis. Its Field Activated Sample Treatment (FAST) technology uses electrical lysing and sample treatment to enable rapid detection of infectious agents directly from blood. The company raised US$20M in a Series A to finance ongoing product development and team expansion. Qvella intends to deploy the funding to continue developing its technology and grow its team. The technology is being positioned for use alongside Antibiotic Stewardship programs to accelerate clinical decisions, improve patient outcomes, and reduce hospital stays and treatment costs. Tino Alavie is the company's founder, president and CEO.

Total raised

$40M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2017